BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zhejiang Kanova Biopharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Zhejiang Kanova Biopharmaceutical
 's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07519499-1515@assetmemo.bio
DTSTAMP:20261121T010844Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:XKH001: Phase 2 readout est. (NCT07519499)
DESCRIPTION:XKH001\, phase 2\, Chronic Obstructive Pulmonary Disease.\nStud
 y: Phase II Clinical Study to Evaluate the Efficacy and Safety of XKH001 I
 njection\nEstimated primary completion: 1 December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/xkh001#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07519499
URL:https://assetmemo.bio/drug/xkh001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
